{"id":"taxotere-cisplatin-5fu","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Taxotere's mechanism of action involves binding to tubulin, preventing microtubule formation and function, which is essential for cell division. Cisplatin forms platinum-DNA adducts, leading to DNA damage and triggering cell death through apoptosis. 5-FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis and repair, thereby disrupting these processes and inducing cell death.","oneSentence":"Taxotere (docetaxel) works by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA, causing DNA damage and triggering cell death. 5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:54.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Stomach cancer"}]},"trialDetails":[{"nctId":"NCT01565109","phase":"PHASE2","title":"NESC: Neoadjuvant Treatment of Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Recherche clinique","startDate":"2009-03","conditions":"Gastric Adenocarcinoma","enrollment":34},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT00005060","phase":"PHASE3","title":"Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1999-11","conditions":"Gastric Cancer","enrollment":240},{"nctId":"NCT00004873","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1999-08","conditions":"Gastric Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Taxotere-Cisplatin-5FU","genericName":"Taxotere-Cisplatin-5FU","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taxotere (docetaxel) works by inhibiting microtubule dynamics, disrupting cell division, and inducing apoptosis in cancer cells. Cisplatin is a platinum-based alkylating agent that cross-links DNA, causing DNA damage and triggering cell death. 5-Fluorouracil (5-FU) is a thymidylate synthase inhibitor that disrupts DNA synthesis and repair. Used for Non-small cell lung cancer, Breast cancer, Stomach cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}